Moreover, joint administration of ganetespib and lapatinib not only induced enhanced early apoptosis and G0/G1 arrest, but also depleted the aberrant nuclear transcription factors STAT3 and its downstream signaling partners, thought to be associated with the mechanism of lapatinib resistance in HER2-positive breast cancer cells. The gene discussed is STAT3; the disease is breast cancer.